In a filing to the Securities and Exchange Commission, Alexion announced it has settled its US patent eculizumab dispute with Amgen.
As part of the settlement, Amgen will terminate its three US inter partes review proceedings challenging Allexion’s eculizumab patents, and receive a non-exclusive, royalty-free license to supply eculizumab in the US from 01 March 2025.
.